CCNE1 and ovarian cancer: For example, a score defined by any changes “CCNE1 amplification, RB1 two-copy loss, CDKN2A two-copy loss, KRAS amplification, NF1 (gene of transcription factor Neurofibromin 1) mutations, ERBB2 (gene of HER2) amplification, MYC amplification, and MYCL1 (gene of transcription factor L-Myc) amplification” was used as predictor for sensitivity of HGSOC ovarian cancer to gemcitabine and ATRi [45].